{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-25-000017","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.881833+00:00","generated_at":"2026-05-26T23:42:18.784106+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Exelixis Q4 2024 rev $567M, GAAP EPS $0.48; FY2024 rev $2.17B, EPS $1.76","bullets":["Total revenues $566.8M for Q4 2024, up 18% YoY; FY2024 total rev $2.17B, up 18% YoY.","GAAP diluted EPS $0.48 (Q4 2024) vs $0.27 (Q4 2023); FY2024 $1.76 vs $0.65.","Non-GAAP diluted EPS $0.55 (Q4 2024) vs $0.33; FY2024 $2.00 vs $0.90.","Cabozantinib franchise U.S. net product revenues $515M (Q4), $1.81B (FY2024), up from $429M and $1.63B."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-25-000017","json":"https://secwatch.observer/filing/0000939767-25-000017.json","markdown":"https://secwatch.observer/filing/0000939767-25-000017.md","text":"https://secwatch.observer/filing/0000939767-25-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/0000939767-25-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/exel-20250211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:42:18.784106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}